A human monoclonal antibody that binds serotype A botulinum neurotoxin

Hybridoma

Volumn 27, Issue 1, 2008, Pages 11-17

  Adekar, Sharad P ^a,b   Jones, R Mark ^b   Elias, M D ^b   Al Saleem, Fetweh H ^b   Root, Michael J ^b   Simpson, Lance L ^b   Dessain, Scott K ^a,b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; EPITOPE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TELOMERASE;

ANTIBODY AFFINITY; ARTICLE; BLOOD CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYBRIDOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SERODIAGNOSIS; SEROTYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; CELL FUSION; CELL LINE, TUMOR; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; INTERLEUKIN-6; LYMPHOMA, NON-HODGKIN; MICE; MULTIPLE MYELOMA; PROTEIN BINDING; TELOMERASE;

MURINAE;

EID: 39749178435     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.0536     Document Type: Article

References (31)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, and Tonat K: Botulinum toxin as a biological weapon: medical and public health management. Jama 2001;285:1059-1070.
2. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, and Marks JD: Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 2005;73:5450-5457.
3. Simpson LL: Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-193.
4. Bavari S, Pless DD, Torres ER, Lebeda FJ, and Olson MA: Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine 1998;16:1850-1856.
5. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, and Stevens RC: Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun 1997;65:1626-1630.
6. Marks JD: Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 2004;19:S101-108.
7. Greenfield RA, and Bronze MS: Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 2003;8:881-888.
8. Wein LM, and Liu Y: Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci USA 2005;102:9984-9989.
9. Zilinskas RA: Iraq's biological weapons. The past as future? JAMA 1997;278:418-424.
10. Arnon SS: Infant Botulism. In: Textbook of Pediatric Infectious Diseases, R.D. Feigin, J. Cherry, G.J. Demmler, and S. Kaplan (eds.). W.B. Saunders, Philadelphia, 2004, pp. 1758-1766.
11. Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, and Langford MJ: Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 1999;19:S35-38.
12. Siegel LS: Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26:2351-2356.
13. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, and Marks JD: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002;99:11346-11350.
14. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, and Simpson LL: An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006;318:1343-1351.
15. Dessain SK, Adekar SP, and Berry JD: Exploring the native human antibody repertoire to create anti-viral therapeutics. Curr Top Microbiol Immunol 2008;317:155-183.
16. Carroll WL, Thielemans K, Dilley J, and Levy R: Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 1986;89:61-72.
17. Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL, Goldsby RA, and Weinberg RA: High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods 2004;291:109-122.
18. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959.
19. Kiyatkin N, Maksymowych AB, and Simpson LL: Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun 1997;65:4586-4591.
20. Maksymowych AB, and Simpson LL: Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 2004;310:633-641.
21. Edelhoch H: Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967;6:1948-1954.
22. Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, Williamson RA, Burton DR, and Pluckthun A: Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 2006;363:75-97.
23. Campbell MJ, Zelenetz AD, Levy S, and Levy R: Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992;29:193-203.
24. Coronella JA, Telleman P, Truong TD, Ylera F, and Junghans RP: Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells. Nucleic Acids Res 2000;28:E85.
25. Lefranc MP, Giudicelli V, Kaas Q, Duprat E, Jabado-Michaloud J, Scaviner D, Ginestoux C, Clement O, Chaume D, and Lefranc G: IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2005;33:D593-597.
26. Pearce LB, Borodic GE, First ER, and MacCallum RD: Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
27. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, and Crowe JE Jr: Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 2007;44:2173-2183.
28. Shlomchik M, Litwin S, and Weigert M: The influence of somatic mutation on clonal expansion. Prog Immunol 1989;7:415-423.
29. Pless DD, Torres ER, Reinke EK, and Bavari S: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immunol 2001;69:570-574.
30. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, and Chapman ER: SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312:592-596.
31. Mason JT, Xu L, Sheng ZM, He J, and O'Leary TJ: Liposome polymerase chain reaction assay for the sub-attomolar detection of cholera toxin and botulinum neurotoxin type A. Nat Protoc 2006;1:2003-2011.